Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 15 results
Filters: First Letter Of Title is G  [Clear All Filters]
Found 15 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

G

Schwarze-Zander C, Blackard JT, Zheng H, et al. "GB virus C (GBV-C) infection in hepatitis C virus (HCV)/HIV-coinfected patients receiving HCV treatment: importance of the GBV-C genotype." J. Infect. Dis.. 2006;194(4):410-9.
Stapleton JT, Chaloner K, Zhang J, et al. "GBV-C viremia is associated with reduced CD4 expansion in HIV-infected people receiving HAART and interleukin-2 therapy." AIDS. 2009;23(5):605-10.
Ranade K, Geese WJ, Noor M, et al. "Genetic analysis implicates resistin in HIV lipodystrophy." AIDS. 2008;22(13):1561-8.
Pillai SK, Pond SLKosakovs, Liu Y, et al. "Genetic attributes of cerebrospinal fluid-derived HIV-1 env." Brain. 2006;129(Pt 7):1872-83.
Cespedes MS, Kerns SL, Holzman RS, McLaren PJ, Ostrer H, Aberg JA. "Genetic predictors of cervical dysplasia in African American HIV-infected women: ACTG DACS 268." HIV Clin Trials. 2013;14(6):292-302.
Bartha I, Carlson JM, Brumme CJ, et al. "A genome-to-genome analysis of associations between human genetic variation, HIV-1 sequence diversity, and viral control." Elife. 2013;2:e01123.
Johnson DH, Venuto C, Ritchie MD, et al. "Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202." Pharmacogenet. Genomics. 2014;24(4):195-203.
Henrich TJ, McLaren PJ, Rao SSP, et al. "Genome-Wide Association Study of Human Immunodeficiency Virus (HIV)-1 Coreceptor Usage in Treatment-Naive Patients from An AIDS Clinical Trials Group Study." Open Forum Infect Dis. 2014;1(1):ofu018.
Leger PD, Johnson DH, Robbins GK, et al. "Genome-wide association study of peripheral neuropathy with D-drug-containing regimens in AIDS Clinical Trials Group protocol 384." J. Neurovirol.. 2014;20(3):304-8.
Holzinger ER, Grady B, Ritchie MD, et al. "Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants." Pharmacogenet. Genomics. 2012;22(12):858-67.
Wanga V, Venuto C, Morse GD, et al. "Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202." Pharmacogenet. Genomics. 2015;25(9):450-61.
Lehmann DS, Ribaudo HJ, Daar ES, et al. "Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols." Pharmacogenet. Genomics. 2015;25(2):51-9.
Lorenzana SB, Hughes MD, Grinsztejn B, et al. "Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial." AIDS. 2012;26(9):1083-93.
Anderson JA, Jiang H, Ding X, et al. "Genotypic susceptibility scores and HIV type 1 RNA responses in treatment-experienced subjects with HIV type 1 infection." AIDS Res. Hum. Retroviruses. 2008;24(5):685-94.
McMahon DK, Zheng L, Hitti J, et al. "Greater suppression of nevirapine resistance with 21- vs 7-day antiretroviral regimens after intrapartum single-dose nevirapine for prevention of mother-to-child transmission of HIV." Clin. Infect. Dis.. 2013;56(7):1044-51.